The U.S. FDA approved Merck's once-daily oral two-drug combination of doravirine (100 mg) and islatravir (0.25 mg), branded as Idvynso, for treating HIV-1 in virologically suppressed adults as a regimen switch. 1 3 4 Approval announced on April 21, 2026, supported by Week 48 data from Phase 3 trials MK-8591A-051 and MK-8591A-052 involving 708 participants. 4 5 In Trial 052, 1% of Idvynso switchers had viral load ≥50 copies/mL at Week 48 vs. 1% on Biktarvy; in Trial 051, 1% vs. 5% on baseline therapy. 4 Doravirine is already approved as Pifeltro; islatravir is investigational; regimen is non-inferior to three-drug standards without an integrase inhibitor. 1 5 Sources: 1. https://www.marketscreener.com/news/us-fda-approves-merck-s-combination-hiv-treatment-ce7f59dbdd8af526 3. https://www.investing.com/news/stock-market-news/us-fda-approves-mercks-combination-hiv-treatment-4626858 4. https://au.investing.com/news/company-news/fda-approves-mercks-idvynso-for-hiv1-treatmen...
- Get link
- X
- Other Apps